Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00715442 · ClinicalTrials.gov registry record · Phase 2

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

A Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
50
Enrollment target
2
Study locations

NCT00715442: Active Phase 2 study of Renal Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

NCT00715442 is a Phase 2 study of Renal Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00715442, a Phase 2 study of Renal Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

Primary Outcome

TTP is defined as the time interval between treatment starts and disease progression or death, whichever occurred first, assessed each cycle (42 days).

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG Sunitinib
  • PROCEDURE Nephrectomy

Study Locations (2)

Texas

  • Baylor College of Medicine - Houston
  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2008-06-24
Est. Completion 2026-12-04
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT00715442 still lists

NCT00715442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.

NCT00715442 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00715442 about?

NCT00715442 is a clinical study titled "Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)". The goal of this clinical research study is to learn if Sutent® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.

What is the current status of trial NCT00715442?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-06-24. Estimated completion is 2026-12-04.

What conditions does trial NCT00715442 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00715442?

The interventions under investigation include: Sunitinib (DRUG), Nephrectomy (PROCEDURE).

Who is sponsoring clinical trial NCT00715442?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00715442 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00715442's enrollment target sits among peer trials

50 78th of 121 higher than 43 of 121 other Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00715442, the US trial registry maintained by the National Library of Medicine. NCT00715442 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.